Special Issue "Cancer Immunology Focus: Cellular & Molecular Immunology"
Deadline for manuscript submissions: 31 August 2022.
Interests: cancer therapy
A cure for cancer remains elusive. Conventional cancer treatment, such as chemotherapy, radiotherapy, and targeted therapy, are showed improvements for cancer patients. However, patients eventually relapse and develop resistance to conventional treatments. Immunotherapy of cancer is a rapidly evolving field and showed significant improvements for cancer patients in terms of survival and quality of life for multiple cancer including hematological and solid malignancies. Several types of immune therapy ongoing including, activating immune system against cancer cell through checkpoints inhibitor, CAR-T, monoclonal antibody, vaccine, ati-cancer drug and suppressing immune cell inhibitor such as MDSC and Treg. In this special issue, we plan to focus invitro and invivo studies of cellular and molecular mechanisms of immunotherapy for cancer treatment. Furthermore, we will discuss the pre- clinical, clinical, and experimental evidence to uncover the mechanisms related to immunotherapy and combination therapeutic approaches. We warmly welcome all scientists working in these fields are cordially invited to submit their manuscripts to our special issue.
We look forward to receiving your contributions.
Dr. Pasupathi Sundaramoorthy
Dr. D. S. Prabakaran
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.